

Role of Measurement of Interleukin 10 in Idiopathic (Immune) Thrombocytopenic Purpura -ITP

Thesis

Submitted for Partial Fulfillment of Master Degree
in Clinical Hematology

By

Heba Ahmed Tolba El-sayed

MB.B.Ch.
Zagazig University

Supervised by

Prof. Dr. Hanan Hamed

*Professor of Internal Medicine & Clinical Hematology
Faculty of Medicine- Ain Shams University*

Dr. Mohamed Moussa

*Professor of Internal Medicine and Clinical Hematology
Faculty of Medicine-AinShamsUniversity*

Dr. Hanaa Fathey

*Assistant Professor of Internal Medicine and Hematology
Faculty of Medicine- Ain Shams University*

**Faculty of Medicine
Ain Shams University**

2017

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

قالوا

سبحانك لا علم لنا
إلا ما علمتنا إنك أنت
العليم العظيم

صدق الله العظيم

سورة البقرة الآية: ٢٢



Acknowledgments

*First of all and above all great thanks to **ALLAH** whose blessings on me cannot be counted.*

*The sincerest thanks, deepest appreciation and greatest admiration to my **Prof. Dr. Hanan Hamed**, Professor of Internal Medicine & Clinical Hematology, Faculty of Medicine- Ain Shams University, for her constructive keen supervision, Fruitful criticism, continuous support and encouragement to complete this work. I really have the honor to complete this work under her supervision.*

*I feel greatly indebted to **Dr. Mohamed Moussa**, Professor of Internal Medicine and Clinical Hematology, Faculty of Medicine- Ain Shams University, for his trustful help, sincere guidance, continuous support and assistance.*

*Finally, I would like to thank **Dr. Hanaa Fathey**, Assistant Professor of Internal Medicine and Hematology, Faculty of Medicine- Ain Shams University, for the efforts and time she has devoted to accomplish this work.*

*Last but not least, I can't forget to thank all members of my **Family**, specially my **Husband** and my **Parents**, for their support and care.*

Candidate

 *Heba Ahmed Tolba*

List of Contents

<i>Subject</i>	<i>Page No.</i>
List of Tables.....	i
List of Figures	v
Introduction	1
Aim of the Work.....	6
Review of Literature	
Platelet Abnormalities	7
Interleukin-10	60
Relation between IL10 and ITP.....	86
Patients and Methods.....	96
Results.....	Error! Bookmark not defined.
Discussion	120
Summary	134
Conclusion and Recommendations.....	137
References	138
Arabic Summary	—

List of Abbreviations

Abbrev.	Full term
ADP	: Adenosine di-phosphate
AITP	: Autoimmune thrombocytopenic purpura
ALPS	: Autoimmune lymphoproliferative syndrome
APCs	: Antigen presenting cells
cAMP	: Cyclic adenosine mono phosphate
CTL	: Cytotoxic T lymphocytes'
CVID	: Common variable immunodeficiency
DCs	: Dendritic cells
DXM	: Dexamethasone
EBV	: Epstein–Barr virus
GM-CSF	: Granulocyte-macrophage colony stimulating factor
GP	: Glycoproteins
H influenza	: Hemophilus influenzae
HCV	: Hepatitis c virus
HIV	: Human immunodeficiency virus
IgG	: Immunoglobulin G
IL	: Interleukin
IL-10R	: IL-10 receptor
INF	: Interferon
ITP	: Idiopathic thrombocytopenic purpura
IVIG	: Intravenous immunoglobulins
JAK	: Janus kinase
KIR	: Killer cell immunoglobulin-like receptor

List of Abbreviations

LSD	: Least Significant Difference
MAPK	: mitogen-activated protein kinase
M-CSF	: macrophage colony stimulating factor
MHC	: Major histocompatibility
NK	: Natural killer
NSAIDS	: Non-steroidal anti-inflammatory drugs
Os	: oxidative stress
PCD	: programmed cell death
PDGF	: Platelet-derived growth factor
PF4	: Platelet factor 4
RBCs	: Red blood cells
RES	: Reticuloendothelial system
SD	: Standard deviation
STAT	: Signal trasducers and activator of transcription
TGF-β	: Transforming growth factor beta
Th	: T helper cell
TNF-β	: Tumor necrosis factor-beta
TPO	: Thrombopoietin
Tregs	: Regulatory T cells
TXA2	: Thromboxane A2
Tyk	: Tyrosin kinase
VEGF	: vascular endothelial growth factor
vWF	: von Willebrand factor
βTG	: β -thromboglobulin

List of Tables

Table No.	Title	Page No.
Table (1):	Pathophysiologic classification of thrombocytopenia	16
Table (2):	Recommendations for Initial Treatment of Immune Thrombocytopenia Patients with Platelet Counts <20,000-30,000/ μ l. (<i>Liel et al., 2014</i>)	51
Table (3):	Characteristics of the treatments used in refractory chronic idiopathicthrombocytopenic purpura.....	56
Table (4):	Cellular Homologs of Human IL-10	70
Table (5):	Cellular sources of IL-10 (<i>Asadullah et al., 1999b</i>)	72
Table (6):	Effect of IL-10 on immune cells (<i>Asadullah et al., 1999b</i>) ...	79

List of Figures

Figure No.	Title	Page No.
Figure (1):	Light microscopy of Wright-stained smear reveals platelets as small, anucleated fragments with occasional reddish granule (<i>Gawaz, 2001</i>).	8
Figure (2):	Scanning electron micrograph of blood cells. From left to right: human erythrocyte, activated platelet, leukocyte(<i>Borsig, 2008</i>).....	8
Figure (3):	Activated platelets showing pseudopodia emission (x5, 000)(<i>Gawaz, 2001</i>).....	9
Figure (4):	Schematic diagram of platelet(<i>Jennifer et al., 2013</i>).	11
Figure (5):	Platelets adhesion and aggregation (<i>Varga et al., 2008</i>)	12
Figure (6):	Steps of hemostasis and the role of platelets in the formation of platelet plug (<i>Wei et al., 2009</i>).....	15
Figure (7):	Petechia on the tongue in a person with platelets of 3 due to ITP(<i>Leamor Kahanov,et al.</i>).....	19
Figure (8):	Purpura spots(<i>Leamor Kahanov,et al.</i>).....	19
Figure (9):	Immune dysregulation in ITP(<i>Wajeeha, 2008</i>)	20
Figure (10):	Model of relationship of contributing factors in ITP (<i>Cuker et al., 2010</i>)	21
Figure (11):	Multi-step disorders in ITP. (1) Self-antigen generation, (2) T, B central and peripheral tolerance failure, (3) activation of T–B cells and (4) effector phase that lead to platelet clearance. (#) Single dysfunction does not always lead to clinical symptom, for the final stage of antibody production usually needs 1, 2 and 3(<i>Amira, 2014</i>).	23
Figure (12):	T cell immune abnormalities in ITP pathogenesis. Immune thrombocytopenia pathogenesis is a complicated process. T cell immune abnormalities are involved in ITP pathogenesis. These abnormalities include platelet auto-antigen reactive cytotoxic T cells, abnormal numbers and functions of T regulatory cells, loss of Th1/Th2 balance, megakaryocyte maturation abnormalities and abnormal T cell anergy(<i>Xuebin et al., 2014</i>).	30
Figure (13):	Schematic of shifts in the T-cell balance in ITP(<i>Cines et al., 2009</i>).	31
Figure (14):	Mechanisms of central and peripheral T cell tolerance. (1) Fas/FasL pathway induces the activated T cells to apoptosis, (2) inhibitory cell surface molecules help T cell anergyand (3) regulatory T cells secrete a profile of suppressive cytokines(<i>Zhou et al., 2005</i>).	33

Figure (15):	Antiplatelet-antifaody-induced destruction of platelets (P) in chronic idiopathic thrombocytopenic purpura (<i>Levine, 2004</i>).	37
Figure (16):	Peripheral blood and Bone marrow smears in ITP	49
Figure (17):	Therapy of adult chronic idiopathic thrombocytopenic purpura in adults(other forms of this disease are treated differently, hence the need for the qualifiers).Emergency treatment is given as needed for extremely low platelet counts (5000–10,000/ μ l) or for active bleeding. Initial treatment is usually started with prednisonealthough some physicians prefer periodic anti-D (antibody against erythrocyte RhDantigen) or pulsed dexamethasone. Treatment of refractory patients usually proceedsin the order shown; experimental therapy can be given at any time, depending on thetoxicity of the treatment relative to that of the standard therapies.....	52
Figure (18):	Treatment algorithm for ITP(<i>Nomura et al., 2016</i>).....	59
Figure (19):	a.) Stereo diagram of IL-10 monomer, hydrophobic residues marked in red (pdb code 2ILK); b.) Stereo diagram of IL-10 dimer, monomers are shown in violet and green. Disulfide bonds are in yellow. All figures are made with program RIBBONS (<i>Karan et al., 2016</i>).	71
Figure (20):	Three-dimensional structure of hIL-10	72
Figure (21):	Schematic diagram of class II cytokine receptor complexes. The horizontal box represents the cell membrane. Functional receptor pairs are labeled (high-affinity receptor first) and shown as black (high affinity) and gray (low affinity) vertical boxes. Cytokines that interact with a particular receptor pair are shown at the top of each receptor pair. IL-22BP is a soluble IL-22 receptor antagonist (<i>Data from refs. 1 and 6–10.</i>)	75
Figure (22):	Stereo diagram of hIL-10/sIL-10R1 complex (pdb code 1J7V) receptor molecules are in orange, IL-10 dimer has the same color code as in figure 1b (<i>Ruiz-Gómez et al., 2016</i>).	76
Figure (23):	Effects of IL-10 on the Th1/Th2 dysbalance. An immune deviation toward a type 1 cytokine pattern is a typical finding in several indications such as psoriasis, rheumatoid arthritis	77
Figure (24):	Template-based resc scaffolding strategy. 3D functional descriptors representing the side chain functionalities of selected IL-10R1 binding residues (yellow sticks) are used to define the 3D pattern syntax query R-<2,6>-R-<4,5>-Y- to search for seeding templates in PDB. One of the best hits, used as seeding template (2ACA149-157, in green), is shown superimposed to the selected IL-10R1 relevant residues for molecular recognition. Molecular images created with PyMOL.	78

Figure (25): Schematic of shifts in the T-cell balance in ITP	81
Figure (26): The opposing functions of IL-10 on regulatory T-cell subsets. IL-10 acts on Foxp3+ TR cells to enhance Foxp3 and IL-10 expression, and sustain regulatory capacity, whereas IL-10 acts on DN T cells to enhance apoptosis. Notably, both Foxp3+ TR and DN T cells are IL-10 producers, potentially allowing both autocrine and paracrine effects of IL-10(<i>Pierson et al., 2010</i>).....	84

ABSTRACT

Biological markers useful for defining patient with newly diagnosed pt immune thrombocytopenic purpura (ITP) who are likely to develop the chronic form of the disease are partially lacking. The purpose of this study was to assess the clinical role of cytokines in patient with ITP and correlate its levels with different disease stages.

20 patient with ITP at the onset of their disease, 40 chronic, and 30 healthy matched controls enrolled in this study. Serum levels of IL10 was measured in all patient using quantitative immunoenzymatic assays.

Serum IL10 levels were significantly higher in patients with an acute evolution of ITP than in either healthy controls or patients with chronic ITP.

Conclusion. IL-10 seems to predict the clinical course of ITP, as it is significantly higher at the onset of disease in patients who obtain disease remission in less than 1 year.

Keywords: immune thrombocytopenic purpura, cytokines, IL10 and adult.

Introduction

Idiopathic thrombocytopenic purpura is an acquired disorder characterized by decreased number of circulating platelets known as thrombocytopenia and resulting in subnormal platelet counts.

Epidemiological studies have revealed that the annual incidence of newly diagnosed itp is 4-5\100.000 and that approximately 75 per 100 of cases are of the acute type. ITP is classified by duration into newly diagnosis, persistent (3-12 months) and chronic (more than 12 months) (*Stevens et al., 2006*).

Antiplatelet antibodies are responsible for platelet destruction by the reticuloendothelial system and probably for inhibition of megakaryopoiesis. Most cases are considered primary whereas the rest is secondary (attributed to other cause: SLE ,Evan syndrome, HIV and post vaccination). (*Johnsen, 2012*).

A normal human platelet count ranges from 150,000 to 450,000 platelets per microliter of blood. Thrombocytopenia refers to a disorder in which there is a relative decrease in platelet count. One common definition of thrombocytopenia that requires emergency treatment is a platelet count below 50,000 per microliter (*Houghton et al., 2010*).

Thrombocytopenia symptoms ranging from no symptoms up to excessive bleeding, including nose bleeds and easy bruising according to platelet count. Thrombocytopenia arises from one of three reasons: the bone marrow may not produce enough platelets; too many platelets may be broken down in the blood; or too many platelets may be destroyed in the liver or spleen. Thrombocytopenia can be caused by a variety of conditions or medications(*Furlan et al.,2001*).

Purpura may be caused by spontaneous bleeding under the skin in form of petechiae that may occur on feet and leg and it is painless, round and pinpoint (1 to 3 mm in diameter) petechiae usually appear and fade, ecchymoses. Larger than petechiae, ecchymoses are purple, blue or yellow-green areas of skin that vary in size and shape. They can occur anywhere on the body(*Stasi et al., 2009*).

Idiopathic (immune) thrombocytopenic purpura (ITP) is a heterogeneous clinical disorder characterized by immune-mediated platelet destruction. ITP is usually a benign, self-limiting disease. However, approximately 20% of newly diagnosed ITP progress to a chronic form defined according to standardised criteria (*Rodeghiero et al.,2009*).

The clinical differences between newly diagnosed and chronic ITP suggest the existence of different pathophysiological mechanisms in two forms humoral and

cellular immunity and inadequate platelet production in the development of this condition (*Provan et al.,2010*).

Manifests as a bleeding tendency, easy bruising (purpura), or extravasation of blood from capillaries into skin and mucous membranes (petechiae). Although most cases of acute ITP, are mild and self-limited, intracranial hemorrhage may occur when the platelet count drops below $10 \times 10^9/\text{L}$ ($< 10 \times 10^3/\mu\text{L}$); this occurs in 0.5-1% of children, and half of these cases are fatal. (*Butros et al., 2007*) Isolated thrombocytopenia in complete blood cell count and peripheral blood smear is the hallmark of ITP. Bone marrow aspiration and biopsy in patients with ITP shows a normal-to-increased number of megakaryocytic in the absence of other significant abnormalities and it also used as a screening for treatment includes corticosteroids In adults older than 60 years, biopsy is used to exclude myelodysplastic syndrome or leukemia (*Calpin et al., 2006*).

Serum levels of T helper (Th) type 1, Th2 and T-regulatory associated cytokines, such as interferon (IFN) γ , tumour necrosis factor (TNF) α , and interleukin (IL) 2, IL6, IL10, and markers of thrombopoiesis, such as reticulated platelet count and thrombopoietin, were assessed in different phases of ITP in patients and in healthy controls might be considered predictors of ITP progression(*Nugent et al.,2009*).

Interleukin-10 is an important immunoregulatory and an anti-inflammatory cytokine and an inhibitor of IFN- γ synthesis in TH1 cells. Also called human cytokine synthesis inhibitory factor (*Mocellin et al., 2003*)

IL-10 is secreted by macrophages, TH2 cells and mast cells. Cytotoxic T cells also release IL-10 to inhibit viral infection stimulated NK cell activity. It also functions as an inhibitor of TH1 cells and inhibiting macrophages, it functions as an inhibitor of antigen presentation. Also it can promote the activity of mast cells, B cells and certain T cells. The major immunobiological effect of IL-10 is the regulation of the TH1/TH2 balance. IL-10 is involved in assisting against intestinal parasitic infection, local mucosal infection by costimulating the proliferation and differentiation of B cells. Its indirect effects also include the neutralization of bacterial toxins. It is a stimulator of NK cells, enhances their cytotoxic activity (*Murray, 2006*). Based on its immunoregulatory function, IL-10 and ligands for its receptors are tempting candidates for therapeutic intervention in a wide variety of disease states, including autoimmune disorders, acute and chronic inflammatory diseases, cancer, infectious disease, psoriasis and allergic disease.

Modest but significant improvement has been observed in patients with chronic immune disorders after